ESSA Pharma

ESSA Pharma: Developing novel therapies for the treatment of prostate cancer targeting the N-terminal domain of the androgen receptor. ESSA’s lead candidate, EPI-7386, is a first-in-class, highly-selective, oral, small molecule N-terminal domain inhibitor currently being evaluated in a Ph 1 trial as a monotherapy in patients with castration-resistant prostate cancer (CRPC) and in a Phase 1/2 trial in combination with Astellas' and Pfizer’s antiandrogen enzalutamide in patients with metastatic CRPC.
Based in...
US - Pacific
Clinical Stage
Phase l or ll, Pre-Clinical Stage
Disease Space
Men's Health, Oncology
Public, USA
Market Cap
400 Oyster Point Blvd.
South San Francisco, CA 94080
United States

Company Participants at Solebury Trout Hamptons CEO Roundtable 2021

  • David Parkinson, President/CEO

Top 10 Holders of ESSA Pharma Inc

Institution OS (%) Position Mkt Val ($MM) Source Filing Date
BVF Partners LP 19.86 8,748,629 25.98 Stakes 7/11/22
BVF, Inc. 19.85 8,748,629 25.98 13F 12/31/22
Bellevue Asset Management AG 17.92 7,898,583 23.46 13F 12/31/22
Soleus Capital Management LP 8.78 3,869,392 11.49 13F 12/31/22
PFM Health Sciences LP 8.72 3,844,332 11.42 13F 12/31/22
Avidity Partners Management LP 4.21 1,855,400 5.51 13F 12/31/22
Morgan Stanley & Co. LLC 4.19 1,845,681 5.48 13F 12/31/22
Adage Capital Partners GP LLC 2.37 1,042,531 3.10 13F 12/31/22
Ally Bridge Group (NY) LLC 1.84 811,555 2.41 13F 12/31/22
Frazier Life Sciences Management LP 1.37 605,141 1.80 13F 12/31/22
Ownership data is sourced through FactSet.

Stock Market Data

Data is being loaded...
Data is being loaded...
Data is being loaded...
Data is being loaded...
Market Data copyright © 2023 QuoteMedia. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges). RT=Real-Time, RTB=Real-Time BATS BZX Price/Quote; not sourced from all markets, RTN=Real-Time NASDAQ Basic+ Price/Quote; not sourced from all markets, EOD=End of Day, PD=Previous Day. Market Data powered by QuoteMedia. Terms of Use.